Nkarta, Inc. Payments to Acquire Investments
Nkarta, Inc. (NKTX) reported Payments to Acquire Investments of $96.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-10
- Nkarta, Inc. payments to acquire investments for the quarter ending 2026-06-30 was $42.36M, a 38.42% decline year-over-year.
- Nkarta, Inc. payments to acquire investments for the quarter ending 2026-03-31 was $54.28M, a 163.72% increase year-over-year.
- Nkarta, Inc. payments to acquire investments for the quarter ending 2025-12-31 was $91.42M, a 6.65% increase year-over-year.
- Nkarta, Inc. payments to acquire investments for the quarter ending 2025-09-30 was $57.78M, a 45.67% decline year-over-year.
- Nkarta, Inc. payments to acquire investments for fiscal 2025 was $238.56M, a 41.29% decline from fiscal 2024.
- Nkarta, Inc. payments to acquire investments for fiscal 2024 was $406.38M, a 56.16% increase from fiscal 2023.
- Nkarta, Inc. payments to acquire investments for fiscal 2023 was $260.23M, a 32.56% decline from fiscal 2022.
- Nkarta, Inc. payments to acquire investments for fiscal 2022 was $385.89M.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $42.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $96.64M 10-Q · filed 2026-08-10 | $188.06M derived: sum of 3 quarters · filed 2026-08-10 | $245.83M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $54.28M 10-Q · filed 2026-05-12 | $145.69M derived: sum of 2 quarters · filed 2026-05-12 | $203.47M derived: sum of 3 quarters · filed 2026-05-12 | $272.26M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $91.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $149.19M derived: sum of 2 quarters · filed 2026-03-25 | $217.98M derived: sum of 3 quarters · filed 2026-08-10 | $238.56M 10-K · filed 2026-03-25 |
| 2025-09-30 | $57.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $126.57M derived: sum of 2 quarters · filed 2026-08-10 | $147.15M 10-Q · filed 2025-11-10 | $232.87M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $68.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $89.37M 10-Q · filed 2026-08-10 | $175.09M derived: sum of 3 quarters · filed 2026-08-10 | $281.44M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $20.58M 10-Q · filed 2026-05-12 | $106.30M derived: sum of 2 quarters · filed 2026-05-12 | $212.65M derived: sum of 3 quarters · filed 2026-05-12 | $386.92M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $85.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $192.06M derived: sum of 2 quarters · filed 2026-03-25 | $366.34M derived: sum of 3 quarters · filed 2026-03-25 | $406.38M 10-K · filed 2026-03-25 |
| 2024-09-30 | $106.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $280.62M derived: sum of 2 quarters · filed 2025-11-10 | $320.66M 10-Q · filed 2025-11-10 | $384.01M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $174.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $214.31M 10-Q · filed 2025-08-12 | $277.67M derived: sum of 3 quarters · filed 2025-08-12 | $317.06M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $40.04M 10-Q · filed 2025-05-14 | $103.40M derived: sum of 2 quarters · filed 2025-05-14 | $142.79M derived: sum of 3 quarters · filed 2025-05-14 | $215.99M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $63.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $102.75M derived: sum of 2 quarters · filed 2025-03-26 | $175.94M derived: sum of 3 quarters · filed 2025-03-26 | $260.23M 10-K · filed 2025-03-26 |
| 2023-09-30 | $39.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $112.59M derived: sum of 2 quarters · filed 2024-11-07 | $196.88M 10-Q · filed 2024-11-07 | $272.45M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $73.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $157.49M 10-Q · filed 2024-08-13 | $233.06M derived: sum of 3 quarters · filed 2024-08-13 | $368.36M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $84.29M 10-Q · filed 2024-05-09 | $159.86M derived: sum of 2 quarters · filed 2024-05-09 | $295.16M derived: sum of 3 quarters · filed 2024-05-09 | $441.70M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $75.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $210.88M derived: sum of 2 quarters · filed 2024-03-21 | $357.42M derived: sum of 3 quarters · filed 2024-03-21 | $385.89M 10-K · filed 2024-03-21 |
| 2022-09-30 | $135.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $281.84M derived: sum of 2 quarters · filed 2023-11-09 | $310.31M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $146.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $175.01M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $28.47M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |